Clinical trial

Osimertinib for NSCLC With Uncommon EGFR Mutations

NCT05421936

StatusSUSPENDED

Study typeOBSERVATIONAL

Start date2020-09-27

PhaseN/A

Study timeline

Study start (actual)2020-09-27Date precision: day

Registry last updated2023-11-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Carcinoma, Non-Small-Cell Lungunresolved

Genes, erbB-1unresolved

Interventions

OsimertinibDRUG · verified · RxNorm: osimertinib

Sponsors & collaborators

Sheba Medical Centerlead sponsor

AstraZenecacollaborator

Mapped research locations

Ramat GanIsrael1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05421936 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.